Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
Solid Biosciences will present seven accepted abstracts at the ESGCT Annual Congress in Hamburg, October 27-30, 2026. The posters cover SGT-003, the company's Duchenne muscular dystrophy gene therapy now in Phase 1/2 and Phase 3 trials, as well as the POLARIS-101 capsid platform and rAAV manufacturing advances.
Key figures
- Drug Name
- SGT-003
- Phase Of Trial
- Phase 1/2 (INSPIRE DUCHENNE) and Phase 3 (IMPACT DUCHENNE)
- Accepted abstracts
- 7
- Phase of lead program
- Phase 1/2 INSPIRE DUCHENNE and Phase 3 IMPACT DUCHENNE
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.